PL3595693T3 - Formulacje i dawkowanie kannabinoidów - Google Patents

Formulacje i dawkowanie kannabinoidów

Info

Publication number
PL3595693T3
PL3595693T3 PL18767525T PL18767525T PL3595693T3 PL 3595693 T3 PL3595693 T3 PL 3595693T3 PL 18767525 T PL18767525 T PL 18767525T PL 18767525 T PL18767525 T PL 18767525T PL 3595693 T3 PL3595693 T3 PL 3595693T3
Authority
PL
Poland
Prior art keywords
dosage
cannabinoid formulation
cannabinoid
formulation
Prior art date
Application number
PL18767525T
Other languages
English (en)
Inventor
Shmuel Cohen
William Z. Levine
Original Assignee
Izun Pharmaceuticals Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Izun Pharmaceuticals Corp. filed Critical Izun Pharmaceuticals Corp.
Publication of PL3595693T3 publication Critical patent/PL3595693T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL18767525T 2017-03-16 2018-03-16 Formulacje i dawkowanie kannabinoidów PL3595693T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472329P 2017-03-16 2017-03-16
PCT/IL2018/050307 WO2018167795A1 (en) 2017-03-16 2018-03-16 Cannabinoid formulations and dosage
EP18767525.1A EP3595693B1 (en) 2017-03-16 2018-03-16 Cannabinoid formulations and dosage

Publications (1)

Publication Number Publication Date
PL3595693T3 true PL3595693T3 (pl) 2022-03-28

Family

ID=63521893

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18767525T PL3595693T3 (pl) 2017-03-16 2018-03-16 Formulacje i dawkowanie kannabinoidów

Country Status (12)

Country Link
US (2) US20210121416A1 (pl)
EP (1) EP3595693B1 (pl)
JP (1) JP2020510077A (pl)
KR (1) KR102621425B1 (pl)
CN (1) CN110603047A (pl)
AU (1) AU2018235442A1 (pl)
CA (1) CA3056556A1 (pl)
ES (1) ES2908141T3 (pl)
IL (1) IL269305B2 (pl)
PL (1) PL3595693T3 (pl)
RU (1) RU2019131818A (pl)
WO (1) WO2018167795A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022003532A2 (pt) * 2019-08-29 2022-05-24 Izun Pharmaceuticals Corp Composições de cannabis à base de proteínas
CN116157137A (zh) * 2020-08-03 2023-05-23 塞斯帕克有限公司 维持微血管完整性的方法
WO2022070191A1 (en) 2020-10-01 2022-04-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Protein-bound cannabinoid formulations and uses thereof
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04208280A (ja) * 1990-11-30 1992-07-29 Matsushita Electric Ind Co Ltd カンナビノール誘導体とその作製方法及びカンナビノール・タンパク質コンジュゲート
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
AU2015232994B2 (en) * 2014-03-18 2020-05-28 Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions

Also Published As

Publication number Publication date
US20210121416A1 (en) 2021-04-29
RU2019131818A (ru) 2021-04-16
IL269305B1 (en) 2024-07-01
ES2908141T3 (es) 2022-04-27
EP3595693A1 (en) 2020-01-22
IL269305B2 (en) 2024-11-01
IL269305A (en) 2019-11-28
CN110603047A (zh) 2019-12-20
KR102621425B1 (ko) 2024-01-05
EP3595693B1 (en) 2021-12-15
EP3595693A4 (en) 2020-08-26
CA3056556A1 (en) 2018-09-20
BR112019019245A2 (pt) 2020-04-14
KR20190126128A (ko) 2019-11-08
US20230255902A1 (en) 2023-08-17
WO2018167795A1 (en) 2018-09-20
AU2018235442A1 (en) 2019-10-31
RU2019131818A3 (pl) 2021-07-09
JP2020510077A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
IL293377A (en) Hsd17b13 variants and uses thereof
IL289276A (en) Treprostinil derivatives and compositions and uses thereof
HRP20260186T1 (hr) Inkretinski analozi i njihova upotreba
PL3523053T3 (pl) Urządzenie do powlekania i przynależny sposób eksploatacji
PL3603620T3 (pl) Kompozycja liposomowa i kompozycja farmaceutyczna
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
EP3582878A4 (en) SORBENT DEVICES
DK3655038T3 (da) Farmaceutisk sammensætning
PL3319612T3 (pl) Oksysterole i sposoby ich stosowania
PL4335517T3 (pl) Podawanie i dawkowanie diaminofenotiazyn
CY1125728T1 (el) Ενωσεις πυριδιναμινης-πυριδονης και πυριμιδιναμινης-πυριδονης
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
IL269844A (en) Dosing regimens and related compositions and methods
DK3634377T3 (da) Farmaceutisk formulering
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
PL3703518T3 (pl) Formulacja ulegająca aerozolowaniu
MA49905A (fr) Polyesteramines et polyesterquats
DK3583943T3 (da) Farmaceutisk sammensætning
IL282157A (en) Compounds and therapeutic uses thereof
IL269305A (en) Cannabinoid formulations and dosage
MA49837A (fr) Compositions pharmaceutiques
EP3638322A4 (en) DECONTAMINATION FORMULATION
IL274953A (en) Unit operation and use thereof
IL269169A (en) Novel dosage form